CAR-T Cellular Therapy Development

CAR-T Cellular Therapy Solutions

From optimizing CAR-T cell design and evaluating pre-clinical models to discovering response biomarkers and mechanisms of action, together we can advance the field of cellular therapy and improve the human condition.


See All Publications

Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.

Simple Summary: This review summarizes gene-expression profiling insights into the background and origination of diffuse large B-cell lymphomas (DLBCL). To further unravel the molecular biology of these lymphomas, a consortium panel called BLYM-777 was designed including genes important for subtype classifications, genetic pathways, tumor-microenvironment, immune response and resistance to targeted therapies.

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.

Despite the high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, its full capacity is currently limited by the generation of dysfunctional CAR T cells. Senescent or exhausted CAR T cells possess poor targeting and effector functions, as well as impaired cell proliferation and persistence in vivo.

PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the immunosuppressive tumor microenvironment (TME), characterized by high levels of multiple inhibitory factors, including transforming growth factor (TGF)-beta.

Spotlight on CAR-T

Webinar New Approaches for CAR-T Cell Therapies: Technology Symposium featuring GeoMx spatial profiling and nCounter CAR-T Characterization
Webinar Murine March Madness: Contextual reprogramming of CAR-T cells for the treatment of HER2-expressing cancers
Blog Post New approaches to CAR-T therapy
Blog Post Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Poster Molecular Characterization for CAR-T Cell Therapy-Poster

Related Resources

View All Resources
Product Bulletin CAR-T Characterization Panel – Product Bulletin
Blog Post Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog Post Top Ten Challenges in Cancer Immunology & Immunotherapy
Poster CAR-T EU Congress 2019 Poster – A Step Toward Standardization with the nCounter® CAR-T Characterization Panel
Product Bulletin nCounter® Stem Cell Characterization Panel Product Bulletin

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us